Piper Sandler downgraded Akoya Biosciences (AKYA) to Neutral from Overweight with a price target of $2.40, down from $3, to reflect the pending acquisition by Quanterix (QTRX). Given the rationale of the synergies, the firm believes the deal will close.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Quanterix shareholder nominates three board candidates, issues statement
- Akoya Biosciences unveils strategic product roadmap
- Akoya Biosciences selects Argonaut Manufacturing as IVD manufacturing partner
- Quanterix price target lowered to $11 from $15 at TD Cowen
- Akoya Biosciences downgraded to Hold from Buy at Canaccord